Sandoz receives EU approval for subcutaneous injection of Binocrit biosimilar

pharmafile | April 8, 2016 | News story | Medical Communications, Research and Development Sandoz, binocrit, biosimilar, eu approval 

Sandoz has received approval from the European Commission for a type II variation for the addition of a subcutaneous route of administration in Binocrit’s (epoetin alfa) nephrology indication.

This approval is based on data from the SENSE clinical study which evaluated the safety and immunogenicity of HX575 epoetin alfa in the treatment of anaemia associated with chronic kidney disease in pre-dialysis and dialysis patients.

Carol Lynch, global head of biopharmaceuticals at Sandoz, says: “By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients.”

Advertisement

Sean Murray

Related Content

Sandoz opens biosimilar development centre in Slovenia

Sandoz has opened a new biosimilar development centre in Ljubljana, Slovenia, as part of efforts …

Sandoz’ Ondibta receives European Commission approval for diabetes

Sandoz has announced that its Ondibta (insulin glargine) has received approval from the European Commission …

Sandoz launches two new bone disease biosimilars in Europe

Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 …

The Gateway to Local Adoption Series

Latest content